T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.
“We are excited to welcome Simone to T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Her impressive track-record of success in cell therapy manufacturing, analytical development and process development will be invaluable as we scale up our manufacturing activities to support the ongoing Phase 1/2 IMAG1NE study for TK-8001, our T cell receptor engineered T cell therapy specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1.”
Dr. Steiner was previously the Head of Technical Development and Manufacturing at Tigen Pharma where she led all activities related to technical development and manufacturing strategy for a TIL product. From 2010 to 2020, Dr. Steiner was in manufacturing and quality roles at Novartis, most recently as the Head of Process Unit CGT Stein where she designed and constructed a cell therapy manufacturing facility and supported the successful manufacturing of Kymriah. During her tenure, she built the company’s cell therapy production capabilities, hiring and training more than one hundred manufacturing associates. At QSV Biologics, a contract manufacturing organization, Dr. Steiner was responsible for process development for multiple projects and worked on the full renovation of QSV’s cGMP manufacturing facility. She obtained her Ph.D. at ETH Zurich and completed her post doc work at the University of Alberta.
Dr. Steiner added, “T cell receptor-based immunotherapies are a promising modality for the next generation of cancer therapeutics, and T-knife’s platform has the potential to deliver best-in-class TCR-Ts. TK-8001 has already demonstrated potent preclinical activity, and I am excited to support the advancement of this differentiated product candidate, as well as the pipeline of candidates generated from the MyT™ platform.”
About T-knife Therapeutics
T-knife is a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients. Focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), the company’s unique approach leverages its proprietary MyT™ platform, a suite of technologies to enable the advancement of next-generation TCR-Ts for solid tumor cancers.
T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens and commonly shared tumor-driving neoantigens. The company’s lead program targeting MAGE-A1 positive solid tumors is in a Phase 1/2 clinical study. T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for Molecular Medicine together with the Charité – Universitätsmedizin Berlin, and is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management and Versant Ventures. For additional information, please visit the company’s website at www.t-knife.com.
T-knife Therapeutics, Inc.
Chief Business Officer / Chief Financial Officer
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Key information relating to the cash dividend to be paid by Golar LNG Limited29.2.2024 11:50:30 CET | Press release
Reference is made to the fourth quarter 2023 report released on February 29, 2024. Golar LNG Limited (“Golar”), NASDAQ ticker: GLNG, has declared a total dividend of $0.25 per share to be paid on or around March 20, 2024. The record date will be March 12, 2024. Due to the implementation of the Central Securities Depository Regulation (“CSDR”), please note the information below on the payment date for the small number of Golar shares registered in Norway’s central securities depository (“VPS”): Dividend amount: $0.25 per shareDeclared currency: USD. Dividends payable to shares registered in the VPS will be distributed in NOKLast day including right: March 8, 2024Ex-date: March 11, 2024Record date: March 12, 2024Payment date: On or about March 20, 2024. Due to the implementation of CSDR in Norway, dividends payable to shares registered in the VPS will be distributed on or about March 22, 2024. Golar LNG Limited Hamilton, Bermuda February 29, 2024 This information is subject to the disclo
Golar LNG Limited preliminary fourth quarter and financial year 2023 results29.2.2024 11:45:33 CET | Press release
Highlights and subsequent events Golar LNG Limited (“Golar” or “the Company”) reports full year 2023 total operating revenues of $298 million, a net loss attributable to Golar of $47 million inclusive of $331 million of non-cash items1, and Adjusted EBITDA1 of $356 million.Q4 2023 total operating revenues of $80 million, a net loss attributable to Golar of $33 million inclusive of $117 million of non-cash items1, and Adjusted EBITDA1 of $114 million.Total Golar Cash1 of $753 million.FLNG Hilli maintained market leading operational track record and exceeded 2023 production target. FLNG Gimi arrived and moored at the GTA hub offshore Mauritania and Senegal.Maturing commercial prospects for FLNG Hilli redeployment and potential new FLNG opportunities, including contract proposals for 12-20 year employment.2.9 million shares repurchased during 2023 at an average price of $21.27 per share inclusive of 1.3 million shares repurchased during Q4 at an average price of $21.48 per share. Re-sold
Lerøy Seafood Group ASA: Mandatory notification of trade by primary insider29.2.2024 11:27:10 CET | Press release
Sjur S. Malm, CFO of Lerøy Seafood Group ASA (LSG), has today February 29th, 2024 bought 15,000 shares in LSG at an average price of NOK 46.54 per share. Ownership after this transaction is 30,000 shares in LSG. Please see the attached form for further details. This information is subject to the disclosure requirements pursuant to MAR article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment Notification by CFO
Lerøy Seafood Group ASA: Meldepliktig handel for primærinnsider29.2.2024 11:27:10 CET | Pressemelding
Sjur S. Malm, konserndirektør Økonomi og finans i Lerøy Seafood Group ASA (LSG), har i dag den 29. februar 2024 kjøpt 15.000 aksjer i LSG til en gjennomsnittskurs på NOK 46,54 per aksje. Beholdningen etter denne transaksjonen er 30,000 i LSG. Se vedlagte skjema for nærmere detaljer. Denne meldingen legges ut på bakgrunn av reglene i MAR art. 19 og verdipapirhandelloven § 5-12. Vedlegg Notification by CFO
Nordic American Tankers Ltd (NYSE: NAT) – Report as per December 31, 2023 – Dividend is up and solid prospects going forward29.2.2024 11:23:30 CET | Press release
Thursday, February 29, 2024 Dear Shareholders and Investors, Highlights: In 2023, the Net Voyage Revenue for Nordic American Tankers Ltd (NAT) totaled $262.2 million. This is a remarkable improvement from 2022, when Net Voyage Revenue was $168.8 million. Our performance produced a net profit of $98.7 million for 2023, more than six times the $15.1 million result for 2022. Maximizing dividends is a key goal and higher earnings result in higher dividends. The dividend for the fourth quarter of 2023 will be 12 cents ($0.12) per share, up from 6 cents in the previous quarter. This marks our 106th consecutive quarterly dividend. The dividend is payable April 10, 2024 to shareholders on record as of March 20, 2024. The average Time Charter Equivalent (TCE) for our spot vessels during the fourth quarter of 2023 came in at $41,580 per day per ship. Including vessels on term contracts, the total average NAT TCE was $39,170 per day per ship. The daily operating costs per ship are about $9,000, b